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of ELAC2 in prostate cancer, suggest moderate familial
risk, and estimate that risk genotypes in ELAC2 may
cause 2% of prostate cancer in the general population.
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Accession numbers and URLs for data presented herein are
as follows:
Online Mendelian Inheritance in Man (OMIM), http://www
.ncbi.nlm.nih.gov/Omim/ (for prostate cancer [MIM
176807], HPC2/ELAC2 [MIM 605367], Ser-to-Leu change
at amino acid 217 [MIM 605367.0001], and Ala-to-Thr
change at amino acid 541 [MIM 605367.0002]
GenBank, http://www.ncbi.nlm.nih.gov/Genbank/ (for variant
Ser217Leu [AF304370])
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Regarding “Testing for Population Subdivision and
Association in Four Case-Control Studies”
To the Editor:
Ardlie et al. (2002) recently found no evidence for pop-
ulation structure in separate case-control studies of type
2 diabetes and hypertension in U.S. whites and only
weak evidence of structure in a case-control study of
hypertension in African Americans. These results are
consistent with the theoretical results of Wacholder et
al. (2000), who found that the magnitude of bias due
to unrecognized population stratification is likely to be
small under most plausible scenarios. To further evaluate
the potential bias due to stratification for these and other
conditions, we conducted a series of case-control studies
for six common phenotypes in a population-based sam-
ple of U.S. adults.
The study population included 444 unrelated adults
(231 African Americans and 213 non-Hispanic whites)
randomly selected from five U.S. communities as part of
theHypertensionGenetic EpidemiologyNetwork (Hyper-
GEN) of the National Heart, Lung, and Blood Institute
(NHLBI) Family Blood Pressure Program (Williams et al.
2000). The studywas approved by the institutional review
boards at each institution, and appropriate informed con-
sent was obtained from human subjects. Phenotypesmea-
sured included: (1) obesity ( ), (2) hypercholes-BMI  30
terolemia (total plasma mg/dl orcholesterol 240
current use of medications to lower cholesterol), (3) hy-
pertension (systolic blood mmHg, dia-pressure  140
stolic blood mmHg, or current use of med-pressure  90
ications to lower blood pressure), (4) diabetes (fasting
serum mg/dl, nonfastingglucose  126 glucose  200
mg/dl, self-reported physician diagnosis of diabetes, or
current use of hypoglycemic medications), (5) renal dys-
function (serum creatinine  sex-specific 90th percentile
[1.4 mg/dl in men and 1.1 mg/dl in women]), and (6)
cardiovascular disease (self-reported history of heart at-
tack, stroke, or coronary artery bypass surgery). For each
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Table 1
Summary Tests for Population Stratification by Phenotype
Phenotype
NO. OF CASE SUBJECTS
(PREVALENCE)
ALL SUBJECTS,
UNADJUSTED
ALL SUBJECTS,
ADJUSTED FOR
RACE
AFRICAN
AMERICANS
ONLY
WHITES
ONLY
African Americans Whites xs
2 P xs
2 P xs
2 P xs
2 P
Obesity 110 (48%) 82 (39%) 379.5 .33 336.8 .88 329.5 .93 431.9 .01
Hypercholesterolemia 44 (19%) 55 (26%) 401.4 .11 360.9 .59 358.4 .63 362.5 .57
Hypertension 130 (56%) 91 (43%) 456.2 .001 371.9 .43 391.7 .19 384.4 .27
Diabetes 46 (20%) 23 (11%) 507.2 !.001 395.7 .15 373.9 .41 381.4 .30
Renal dysfunction 29 (13%) 11 (5%) 442.5 .005 374.2 .40 388.4 .22 367.6 .50
Cardiovascular disease 30 (13%) 20 (9%) 378.6 .34 373.2 .41 377.1 .36 354.7 .68
phenotype, those who did not meet the case definition
served as control individuals.
We constructed contingency tables and performed x2
tests of association for these six phenotypes with each
of 368 STR markers typed by the NHLBI Mammalian
Genotyping Service at Marshfield, WI (screening set 10).
Like Ardlie et al. (2002), we then computed a statistic,
xs
2, to test for overall differences in allele frequencies
between each set of case individuals and control indi-
viduals (Pritchard and Rosenberg 1999). To simplify the
analysis and ensure that expected values in contingency
tables were sufficiently large ( ) for the classical x21 5
test, we converted each STR marker to a biallelic marker
by selecting one index allele for each marker and then
collapsing all other alleles for that marker into a single
alternative allele. Index alleles for each marker were se-
lected by first choosing alleles with allele frequencies of
at least 15% in both African Americans and whites and
then selecting the allele that demonstrated the largest
absolute difference in allele frequencies between racial
groups.
The prevalence of several of the phenotypes differed
substantially between racial groups (table 1). In crude
analysis pooling both racial groups, the percentage of
markers nominally associated ( ) with each phe-P ! .05
notype was higher than expected, under the null hypoth-
esis, for diabetes (8.4%), hypertension (7.9%), renal dys-
function (7.6%), and hypercholesterolemia (5.4%) but
not for cardiovascular disease (4.9%) or obesity (4.9%).
The summary test for stratification incorporating all 368
markers (i.e., 368 df) was statistically significant for di-
abetes, renal dysfunction, and hypertension (table 1), in-
dicating overall differences in allele frequencies between
case individuals and control individuals. However, after
adjustment for race or stratification by race, there was no
evidence of cryptic stratification for any of the six phe-
notypes, with the possible exception of obesity in whites.
Our results provide further evidence that hidden or
unrecognized population stratification is unlikely to be
a serious threat to the validity of case-control designs
that appropriately account for ethnicity in either the de-
sign or analysis phase of the study (Wacholder et al.
2000; Ardlie et al. 2002). Because of the large number
of markers tested, it is likely that our study was even
more sensitive to subtle background genetic differences
between case individuals and control individuals than
that conducted by Ardlie et al. (2002), which included
only 9 STR markers and 35 SNP markers. We think that
other factors, such as selection bias, chance, publication
bias, gene-environment interactions, and differences in
linkage disequilibrium patterns across study popula-
tions, are more plausible explanations for inconsistency
of results between genetic association studies.
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The ABCA4 Gene in Autosomal Recessive Cone-Rod
Dystrophies
To the Editor:
Recently, Maugeri et al. (2000) reported on the screening
of the ABCA4 gene in 5 patients with autosomal reces-
sive cone-rod dystrophies (CRD) and 15 patients with
sporadic CRD originating from Germany and the Neth-
erlands. The identification of mutations in 13/20 patients
(65%) led the authors to speculate that “Mutations in
the ABCA4 (ABCR) gene are the major cause of auto-
somal recessive cone-rod dystrophy.”
The present study was undertaken to evaluate the
prevalence of ABCA4 mutations in a cohort of 55 pa-
tients affected with autosomal recessive or sporadic
CRD.
Within the huge family of inherited retinal dystro-
phies, the CRD phenotype indicates a specific form of
retinal degeneration in which the cone degeneration ap-
pears early in life with a central involvement of the ret-
ina, followed by a degeneration of rods several years
later (Klevering et al. 2002). This particular form of
retinal dystrophy has long been regarded as “inverse
retinitis pigmentosa” (RP) and can be misdiagnosed as
macular dystrophy in the first stages of the disease.
Indeed, the main symptoms at onset of the disease are
decrease of visual acuity, loss of color discrimination,
and photophobia. The b-wave of the photopic ERG
(cone response) is severely reduced, although the b-wave
of the scotopic ERG is still normal. As the disease pro-
gresses, nyctalopia, progressiveperipheralvisualfielddef-
icit, and decreasing scotopic electroretinogram (ERG)
amplitudes are observed.
Four genes (CRX [MIM 602225], GUCY2D [MIM
600179], GCAP1 [MIM 600364], and HRG4 [MIM
604011]) and two loci have been implicated in auto-
somal dominant CRD (CORD5 [MIM 600977] and
CORD7 [MIM 603649]), whereas two other loci were
reported for autosomal recessive CRD (CORD9 [Dan-
ciger et al. 2001] and CORD8 [MIM 605549]) and one
for X-linked CRD (RPGR [MIM 312610]).
Conversely, the ABCA4 gene, which was identified in
1997 as the Stargardt-causing gene, was later recognized
as responsible for some forms of RP (RP19) and some
CRD, depending on the nature of the ABCA4mutations
and on the remaining protein activity (Allikmets et al.
1997; Martinez-Mir et al. 1997; Cremers et al. 1998;
Gerber et al. 1998; Rozet et al. 1998, 1999).
Sixty-one individuals affected with CRD and 40
healthy relatives belonging to 55 families of various or-
igin were recruited from genetic and ophthalmologic
consultations. In 29/55 families, the disease was un-
doubtedly inherited as an autosomal recessive condi-
tion—23 multiplex families (11/23 consanguineous) and
six simplex patients born to consanguineous parents. In
the 26/55 remaining families, the patients were simplex
cases. The time course of the disease was determined by
interviewing at least one patient per family and, when-
ever possible, all affected siblings of the family. Minimal
criteria for inclusion in the study were initial cone dys-
function and subsequent progressive peripheral disease.
In one affected patient per family, we screened for
mutations the 50 exons of the ABCA4 gene, as well as
the flanking intronic sequences, using denaturing high-
pressure liquid chromatography. On the basis of the sec-
ondary structure of each exon, the screening was per-
formed at 1 or 2 temperatures (mutation detection rate
estimated to be at least 0.98). Exons showing a shift
were directly sequenced.
Sixteen different mutant alleles were identified in 13/
55 patients (i.e., 23.6% of all cases). Among these 13
patients, 2 were homozygotes (from two consanguineous
families), 4 were compound heterozygotes, and 7 were
